February 17, 2022 01:58 PM ESTUpdated February 18, 03:51 PM

Is the clock ticking on Moderna's patent promise? Activists fear South African patents could hinder vaccine production

Nicole DeFeudis

Editor

Citing its commitment to equitable vaccine access, Moderna pledged early on that it wouldn’t enforce its Covid-related IP rights while the pandemic is ongoing. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Is the clock ticking on Moderna's patent promise? Activists fear South African patents could hinder vaccine production

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus

Is the clock tick­ing on Mod­er­na's patent promise? Ac­tivists fear South African patents could hin­der vac­cine pro­duc­tion

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Is the clock ticking on Moderna's patent promise? Activists fear South African patents could hinder vaccine production

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus